Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.59 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL108276 | 1.00 | BHMT (0.59) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL108277 | 1.00 | BHMT (0.59) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL8954847 | 0.98 | BHMT (0.57) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL8954852 | 0.98 | BHMT (0.57) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL29016958 | 0.95 | BHMT (0.54) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL17847432 | 0.95 | BHMT (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL17847431 | 0.95 | BHMT (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Glutamic Acid SCHEMBL12276999 | 0.93 | GRM8 (0.60) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Leucine SCHEMBL28072785 | 0.92 | SLC7A5 (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Leucine SCHEMBL10439303 | 0.92 | SLC7A5 (0.58) | BHMTBHMT2RNPEPGRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011502-A1 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2015-01-08 | — | — | US | disclosed |
| US-8821473-B2 | Methods and compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8795652-B1 | Methods and compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8747385-B2 | Methods and compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2013076586-A2 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENTS | ADVANCED BIOLOGICAL LABORATORIES SA (LU) | 2013-05-30 | — | — | WO | disclosed |
| US-8383158-B2 | Methods and compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120219521-A1 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | ABBOTT CARDIOVASCULAR SYSTEM INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8038991-B1 | High-viscosity hyaluronic acid compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2340843-A1 | Methods and compositions to treat myocardial conditions | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2332553-A1 | Methods and compositions to treat myocardial conditions | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100144635-A1 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7641643-B2 | Methods and compositions to treat myocardial conditions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009105739-A2 | DNA DETECTION BY DNA CHIP | KONKUK UNIVERSITY (KR) | 2009-08-27 | — | — | WO | disclosed |
| US-20080208167-A1 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | STANKUS JOHN | 2008-08-28 | — | — | US | disclosed |
| US-7294334-B1 | Methods and compositions to treat myocardial conditions | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1631299-A2 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | Guidant Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040213756-A1 | Delivering a structurally reinforcing agent to a ventricle comprising solid material to increase compliance; preventing thinning of ventricular infarct zone; crosslinked collagen; pro-fibroblastic and angiogenic agents; drug delivery; cardiovascular disorders | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004091592-A2 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | GUIDANT CORPORATION, V.I. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040208845-A1 | Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2004-10-21 | — | — | US | disclosed |